Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Activating EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05244213
What this trial is testing

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

Who this might be right for
Non-small Cell Lung CancerEGFR Activating Mutation
Guangdong Provincial People's Hospital 35
Large-scale testing (Phase 3)Study completedNCT01121393
What this trial is testing

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungAdenocarcinoma
Boehringer Ingelheim 364
Testing effectiveness (Phase 2)Ended earlyNCT03805841
What this trial is testing

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Who this might be right for
NSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIIC+5 more
Rain Oncology Inc 41
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07182708
What this trial is testing

High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)EGFR Activating MutationResectable Lung Non-Small Cell Carcinoma
Peking University Cancer Hospital & Institute 62
Early research (Phase 1)Study completedNCT03446417
What this trial is testing

ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Zeno Pharmaceuticals, Inc. 34
Post-approval studies (Phase 4)Study completedNCT04511533
What this trial is testing

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Pfizer 101
Testing effectiveness (Phase 2)UnknownNCT01470716
What this trial is testing

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Who this might be right for
NSCLC Stage IINSCLC, Stage IIIA
National Cancer Center, Korea 26
Not applicableLooking for participantsNCT06053099
What this trial is testing

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Who this might be right for
Non Small Cell Lung CancerEGFR Activating MutationEGFR DEL19+1 more
Intergroupe Francophone de Cancerologie Thoracique 300
Testing effectiveness (Phase 2)Study completedNCT01217619
What this trial is testing

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Who this might be right for
Non Small Cell Lung Cancer
Baohui Han 25
Testing effectiveness (Phase 2)Study completedNCT04233021
What this trial is testing

Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Who this might be right for
Non Small Cell Lung Cancer MetastaticLeptomeningeal MetastasisBrain Metastases+1 more
Intergroupe Francophone de Cancerologie Thoracique 57
Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385483
What this trial is testing

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 19
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Early research (Phase 1)Looking for participantsNCT07755397
What this trial is testing

First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

Who this might be right for
NSCLC Patients With EGFR Activating MutationAdenoid Cystic Carcinoma MetastaticAdenoid Cystic Carcinoma of the Head and Neck
Jubilant Therapeutics India Limited 30
Early research (Phase 1)Ended earlyNCT06685718
What this trial is testing

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerLung CancerNSCLC+3 more
BeOne Medicines 33
Testing effectiveness (Phase 2)UnknownNCT03486496
What this trial is testing

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Who this might be right for
Lung AdenocarcinomaEGFR Mutation
Fujian Cancer Hospital 50
Testing effectiveness (Phase 2)WithdrawnNCT02347839
What this trial is testing

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.

Who this might be right for
Lung Cancer
Sun Yat-sen University